Therapy Options in HR+/HER2- Breast Cancer

Expert oncologists Hope S. Rugo, MD, FASCO; Aditya Bardia, MD, MPH; Komal Jhaveri, MD, FACP; Mark Pegram, MD; and Anne O'Dea, MD, review data from recent conferences and discuss updates in the management of HR+/HER2- breast cancer.

EP. 1: Frontline Treatment Strategies for HR+/HER2- Breast Cancer

June 27th 2022

Expert perspectives on the evolving treatment paradigm for patients receiving frontline therapy for HR+/HER2- breast cancer.

EP. 2: CKD4/6 Inhibition in HR+/HER2- BC: Trial Data With Abemaciclib and Ribociclib

June 27th 2022

Focusing on the frontline setting of HR+/HER2- breast cancer, panelists discuss clinical trial data with abemaciclib and ribociclib, respectively.

EP. 3: CKD4/6 Inhibition in HR+/HER2- BC: Trial Data With Palbociclib

July 4th 2022

Panelists share insight on clinical trial data behind use of palbociclib in the frontline setting of HR+/HER2- breast cancer.

EP. 4: HR+/HER2- BC: Selecting a CDK4/6 Inhibitor in the Frontline Setting

July 4th 2022

Taking into account all 3 available CDK4/6 inhibitors in HR+/HER2- breast cancer, experts consider how they’d select frontline therapy in this setting.

EP. 5: HR+/HER2- Breast Cancer: Identifying Barriers to Use of CDK4/6 Inhibition

July 11th 2022

Comprehensive insight on the barriers to CDK4/6 inhibition in HR+/HER2- breast cancer, from both medical and accessibility perspectives.

EP. 6: Real-World Use of CDK4/6 Inhibition in HR+/HER2- Breast Cancer

July 11th 2022

Experts home in on real-world data and resistance mechanisms to discuss practical use of CDK4/6 inhibition in HR+/HER2- breast cancer.v

EP. 7: Frontline Combination Strategies in HR+/HER2- BC

July 18th 2022

A brief review of frontline combination strategies in the context of multiple driver pathways in HR+/HER2- breast cancer.

EP. 8: Is There a Role for CDK4/6 Inhibition in HR+/HER2+ Breast Cancer?

July 18th 2022

Shifting their focus to the HR+/HER2+ setting of breast cancer, expert panelists consider the potential of CDK4/6 inhibition in light of clinical trial data.

EP. 9: Novel Treatment Approaches to Relapsed/Refractory HR+ Breast Cancer

July 25th 2022

Comprehensive insight on novel treatment approaches in the setting of relapsed/refractory HR+/HER2- breast cancer, including oral SERDs, SERMs, and ER PROTAC degraders.

EP. 10: HR+ BC: Is There Still a Role for Everolimus Post–Endocrine Therapy?

July 25th 2022

Panelists briefly consider the ongoing role of everolimus in relapsed/refractory HR+/HER2- breast cancer given recent shifts in the treatment paradigm.

EP. 11: Novel Therapy for Relapsed/Refractory HR+ BC: Oral SERDs

August 1st 2022

A brief overview of oral SERDs currently being investigated in the setting of relapsed/refractory HR+/HER2- breast cancer.

EP. 12: Novel Therapy for Relapsed/Refractory HR+ BC: PI3K Inhibitors

August 1st 2022

Expert perspectives on the current paradigm of PI3K inhibition in the setting of relapsed/refractory HR+/HER2- breast cancer.

EP. 13: Second-Line Use of CDK4/6 Inhibitors in HR+ Breast Cancer

August 8th 2022

Shared insight on the potential role of CDK4/6 inhibitors in the second-line setting of relapsed/refractory HR+/HER2- breast cancer.

EP. 14: ADCs in HR+/HER2- Advanced BC: Results From TROPICS-02 and DESTINY-Breast04

August 8th 2022

Centering discussion on the TROPICS-02 and DESTINY-Breast04 trials, panelists consider the advent of antibody drug conjugates in relapsed/refractory HR+ breast cancer.

EP. 15: Considerations for Use of ADCs in HER2-Low Breast Cancer

August 15th 2022

A brief discussion on the use of antibody drug conjugates in patients with relapsed/refractory breast cancer and HER2-low expression.

EP. 16: Novel Therapy for Relapsed/Refractory HR+ BC: IO Therapy and PARP Inhibition

August 15th 2022

Expert perspectives on trial results with both IO and PARP inhibitor therapy, respectively, in the setting of relapsed/refractory HR+/HER2- breast cancer.

EP. 17: Optimizing Management of HR+/HER2- BC: Future Directions in Care

August 15th 2022

Closing out their discussion on HR+, HER2- breast cancer, expert panelists share their excitement for further evolution in the treatment paradigm.